FDA concerns about Impax lab in Taiwan raise fears of fresh setback for Parkinson's drug; Galectin cites 'social media' for stock plunge;

@FierceBiotech: Nominations are open for our 2014 Women in Biotech report. More | Nomination form | Follow @FierceBiotech

@JohnCFierce: I used to make fun of $PFE's big in-licensing deals (remember Medivation and Alzheimer's?) I'm switching to out-licensing now (neratinib). | Follow @JohnCFierce

@DamianFierce: Just wait until  finds out what people on Friendster are saying. More | Follow @DamianFierce

@EmilyMFierce: Ebola treatments caught in limbo. Nature piece | Follow @EmilyMFierce

> The FDA has raised concerns about Impax Lab's ($IPXL) manufacturing facility in Taiwan, sparking fears that it may further delay the biotech's Parkinson's drug Rytary, which was earlier held up by manufacturing woes in California. Story

> Shares of Galectin Therapeutics ($GALT) got hammered yesterday following a cohort analysis which it insists is positive. Today the biotech blamed "social media" for the meltdown, which included some harsh criticism. Release

Medical Device News

@FierceMedDev: Dental implant player Nobel Biocare is the latest med tech M&A target. Story | Follow @FierceMedDev

@StacyALawrence: Large healthcare customers squeeze med tech supplier Owens & Minor. Article | Follow @StacyALawrence

@VarunSaxena2: AcelRx discusses sublingual painkiller's rejection with concerned investors. FierceDrugDelivery article | Follow @VarunSaxena2

@MichaelGFierce: Scientists test a Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer. More from Newswise | Follow @MichaelGFierce

@EmilyWFierce: Epic Sciences ropes in $PFE and $RHHBY funding to commercialize CTC tests for cancer treatment. FierceDiagnostics story | Follow @EmilyWFierce

> Kickstarter in vogue as funding mechanism for new devices. Story

> What will changes to the Sunshine Act mean for devicemakers? Item

> Coloplast adding 150 jobs in the U.K. to boost chronic care business. Article

Pharma News

@FiercePharma: Popular on FiercePharmaMarketing: Why are Anoro and Breo slow starters? GSK's new quota-free model, critics say. Story | Follow @FiercePharma

@TracyStaton: On $PFE, the market's focus is on EPS beat. 58 cents vs. expected 57. Shares up 1.3% pre-market. PR, ICYMI. Earnings statement (PDF) | Follow @TracyStaton

@EricPFierce: Hikma builds more heft in sterile manufacturing. Say it will take equipment out of closed Ben Venue plant. News | Follow @EricPFierce

@CarlyHFierce: Today in FiercePharmaMarketing: Doom for combo meds? PBMs dump 2-in-1 drugs; 'Name-calling' at FDA. Issue | Follow @CarlyHFierce

> Bayer nabs new OKs for Eylea, Stivarga as top meds skate past forecasts. Story

> A $635M win-win deal boosts Pfizer in vaccines, slims Baxter for spinoff. Article

> Amgen makes deep job cuts to position itself for post Enbrel-world. More

> Will he or won't he? Pfizer CEO scouts big deals, but 'silent' on AstraZeneca rebid. News

Drug Delivery News

> Amid fears of shortage of antibiotics, DNA origami technique developed to combat E. coli, other bugs. Article

> Nanoparticles deliver agents to spur immune system into action against cancer. Story

> Developer of unique delivery technology for eye care expanding in Europe. Item

> Nature-inspired artificial cilia could help move drugs to a target. More

> AcelRx discusses sublingual painkiller's rejection with concerned investors. Article

Diagnostics News

> In Q2, diagnostics venture investment showed some signs of life. More

> Epic Sciences' CTC cancer tests again draw Roche, Pfizer to investor table. Article

> Japan's Konica Minolta, New Jersey Dx outfit to develop heart attack rapid blood test. Story

> Qiagen sees blood cancer biomarker Dx potential in University of Tokyo patents. Article

> Mela Sciences pulls in funding to fuel reimbursement push for melanoma Dx device. Item

Pharma Marketing News

> Doom for combo meds? Express Scripts, CVS dump Horizon Pharma two-in-one drugs. Report

> Name-calling: The FDA needs your ideas for locking down brand monikers. More

> AstraZeneca unit rolls out preemie newspaper ads to fight Synagis limits. More

> Why are Anoro and Breo slow starters? GSK's new quota-free model, critics say. Story

> Merck spokeswoman: Sales layoffs to hit PA-based field reps. Article

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.

Companies including Novartis and Pfizer are contributing to the joint response through actions including the sharing of proprietary compounds